|
|
Article: Rabeprazole Delayed Release Tablets (Aciphex--Eisai Inc. and Janssen Pharmaceutica).(Brief Article)
- Article from:
- Internal Medicine Alert
- Article date:
- September 29, 1999
- Author:
CopyrightCOPYRIGHT 1999 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
THE FDA HAS APPROVED A THIRD PROTON PUMP inhibitor (PPI) for the treatment of duodenal ulcers and gastroesophageal reflux disease (GERD). Rabeprazole (Aciphex) joins omeprazole (Prilosec) and lansoprazole (Prevacid) in this competitive, $3 billion worldwide market. Rabeprazole will be comarketed in this country by Eisai Inc and Janssen Pharmaceutica. The drug is a pyridyl methysulfinyl benzaminidazole, chemically similar to omeprazole. The PPIs inhibit gastric acid secretion by inhibiting the proton pump (H+/K+ ATFase) in the canalicular membrane of gastric parietal cells. [1]
Indications
Rabeprazole is approved for the healing of duodenal ulcers and ...
Related newspaper, magazine, and journal articles:
|
|
Article: New findings reported from University of Kansas describe advances ...
Biotech Week;
October 21, 2009 ;
700+ words
... ... significantly impaired. Rabeprazole augments gastric mucin ... report (see also Acid Reflux Disease). "We have studied ... therefore, the effect of rabeprazole on esophageal mucin ... Kansas City, Acid Reflux Disease, Antiulcer, Digestive ... Gastroenterology, Rabeprazole, Therapy, ...
|
|